Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog

  • 67 Accesses

  • 16 Citations


The effects of HB 699, a non-sulphonyl urea acyl-amino-alcyl benzoic acid derivative, were studied in unanaesthetized dogs. Changes in blood glucose and plasma insulin, glucagon, pancreatic polypeptide and somatostatin were measured after a single intravenous injection. HB 699 caused hypoglycaemia and stimulated insulin secretion in a dosedependent manner. The effects of HB 699 (40 mg/ kg) on pancreatic hormone secretion were compared to those of tolbutamide given at a dose (12 mg/kg) which induced a similar maximal hypoglycaemia. Both drugs caused a similar increase in insulin release (180±32% for tolbutamide and 240±41% for HB 699) lasting for approximately 1 hour. Despite hypoglycaemia, plasma glucagon concentrations were unaltered by either substance. HB 699 caused a marked increase in the secretion of pancreatic polypeptide (220±60% at 30 min) for up to 2 hours, whereas tolbutamide caused no significant change in plasma pancreatic polypeptide levels. In contrast, while tolbutamide caused a significant (45±12%) but short-lived increase in plasma somatostatin concentrations, HB 699 had no significant effect.


  1. 1.

    Geisen K, Hübner M, Hitzel V, Hrstka VE, Pfaff W, Bosies E, Regitz G, Kuhnle HF, Schmidt FH, Weyer R (1978) Acylamino-alkylsubstituierte Benzoe und Phenyl-alkansäure mit blut-glucosesenkender Wirkung. Arzneim Forsch 28: 1081–1083

  2. 2.

    Geisen K, Hitzel V, Hrstka VE, Pfaff W, Regitz G, Weyer R (1977) Acylaminoalkyl-Benzoesäuren, eine neue Klasse blutzuckersenkender Substanzen. 12. Kongreß der Deutschen Diabetes Gesellschaft, Homburg/Saar. Novo-Kongreß-Band und Ergänzungsband mit Dia-Reproduktionen, Vortrag Nr 38

  3. 3.

    Kühnle HF, Hrstka VE, Schmidt FH, Bosies F, Heerdt R, Geisen K (1977) Phenylalkancarbonsäuren als blutzuckersenkende Substanzen. 12. Kongreß der Deutschen Diabetes Gesellschaft, Homburg/Saar. Novo-Kongreß-Band und Ergänzungsband mit Dia-Reproduktionen, Vortrag Nr 18

  4. 4.

    Fussgänger RD, Wojcikowski C (1977) Stimulation of insulin secretion of the isolated perfused rat pancreas by a new hypoglycaemic agent, an acyl-amino-alcyl-benzoic acid derivative. Diabetologia 13: 394–395

  5. 5.

    Blayac JP, Loubatières-Mariani MM, Ribes G (1979) Effets in vitro d'un dérivé acyl-amino-alkyl de l'acide benzoïque: le HB 699, sur la sécrétion d'insuline et de glucagon. J Pharmacol (Paris) 10: 229–238

  6. 6.

    Alric R, Mariani MM, Loubatières A (1965) Importance de l'état des éléments figurés du sang et en particulier de celui des globules rouges sur les valeurs du glucose sanguin mesuré par l'auto-analyseur Technicon. Pathol Biol (Paris) 13: 506–511

  7. 7.

    Hales CN, Randle PJ (1963) Immunoassay of insulin with insulin antibody precipitate. Biochem J 88: 137–146

  8. 8.

    Unger RH, Aguilar-Parada E, Müller W, Eisentraut AM (1970) Studies of pancreatic alpha-cell function in normal and diabetic subjects. J Clin Invest 49: 837–848

  9. 9.

    Heding LG (1971) Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7: 10–19

  10. 10.

    Greenwood FC, Hunter WM, Glover JS (1963) The preparation of I131 labelled human growth hormone of high specific radioactivity. Biochem J 89: 114–123

  11. 11.

    Herbert V, Lau KS, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375–1384

  12. 12.

    Zar JH (1974) Biostatistical analysis. Prentice-Hall, Englewood Cliffs NJ, p 151

  13. 13.

    Loubatières A, Mariani MM, Ribes G, Alric R (1973) Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide). Acta Diabetol Lat 10: 261–282

  14. 14.

    Finney DJ (1964) Statistical method in biological assay, 2nd ed. Griffin and Co, London, p 174

  15. 15.

    Glatt M, Schatz H (1979) Studies on the insulinotropic action of a new hypoglycemic agent, an acyl-amino-alcyl-benzoic acid (HB 699). In: Waldhäusl W, Alberti KGMM (eds) 10th Congress of the International Diabetes Federation, Vienna, Austria, Int Congr Series 481. Excerpta Medica, Amsterdam Oxford, p 75

  16. 16.

    Adrian TE, Bloom SR, Besterman AS, Barnes AJ, Cooke TJ, Russel RC, Faber RG (1977) Mechanism of pancreatic polypeptide release in man. Lancet I: 161–163

  17. 17.

    Marco J, Hedo JA, Villanueva ML (1978) Control of pancreatic polypeptide secretion by glucose in man. J Clin Endocrinol Metab 46: 140–145

  18. 18.

    Marco D, Valverde I (1973) Unaltered glucagon secretion after seven days of sulfonylurea administration in normal subjects. Diabetologia 9: 317–319

  19. 19.

    Loubatières A, Loubatières-Mariani MM, Alric R, Ribes G (1974) Tolbutamide and glucagon secretion. Diabetologia 10: 271–276

  20. 20.

    Lecomte MJ, Luyckx AS, Lefevre PJ (1977) Plasma glucagon and clinical control of maturity-onset type diabetes. Effects of diet, placebo and glipizide. Diabète Métab 3: 239–243

  21. 21.

    Ipp E, Dobbs RE, Arimura A, Vale W, Harris V, Unger RH (1977) Release of immunoreactive somatostatin from the pancreas in response to glucose, aminoacids, pancreozymin, cholecystokinin. J Clin Invest 60: 760–765

  22. 22.

    Efendic S, Enzmann F, Nylen A, Uvnäs-Wallensten K, Luft R (1980) Sulphonylurea (glibenclamide) enhances somatostatin and inhibits glucagon release induced by arginine. Acta Physiol Scand 108: 231–233

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ribes, G., Trimble, E.R., Blayac, J.P. et al. Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia 20, 501–505 (1981). https://doi.org/10.1007/BF00253415

Download citation

Key words

  • Acyl-amino-alcyl benzoic acid derivative
  • hypoglycaemic agent
  • insulin release
  • pancreatic polypeptide
  • glucagon
  • somatostatin
  • tolbutamide
  • unanaesthetized dogs